About connect biopharma holdings ltd - CNTB
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.
CNTB At a Glance
Connect Biopharma Holdings Ltd.
3580 Carmel Mountain Road
San Diego, California 92130
| Phone | 1-858-727-1040 | Revenue | 26.03M | |
| Industry | Pharmaceuticals: Major | Net Income | -15,628,000.00 | |
| Sector | Health Technology | Employees | 62 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CNTB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.927 |
| Price to Book Ratio | 0.829 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.796 |
| Enterprise Value to Sales | -0.666 |
| Total Debt to Enterprise Value | -0.01 |
CNTB Efficiency
| Revenue/Employee | 419,887.097 |
| Income Per Employee | -252,064.516 |
| Receivables Turnover | 24.77 |
| Total Asset Turnover | 0.229 |
CNTB Liquidity
| Current Ratio | 11.458 |
| Quick Ratio | 11.458 |
| Cash Ratio | 11.074 |
CNTB Profitability
| Gross Margin | 97.465 |
| Operating Margin | -86.244 |
| Pretax Margin | -59.175 |
| Net Margin | -60.031 |
| Return on Assets | -13.758 |
| Return on Equity | -16.177 |
| Return on Total Capital | -16.924 |
| Return on Invested Capital | -16.16 |
CNTB Capital Structure
| Total Debt to Total Equity | 0.193 |
| Total Debt to Total Capital | 0.193 |
| Total Debt to Total Assets | 0.176 |
| Long-Term Debt to Equity | 0.026 |
| Long-Term Debt to Total Capital | 0.026 |